Cellebrite DI (CLBT) Cash & Equivalents (2020 - 2026)

Cellebrite DI has reported Cash & Equivalents for 7 years, with the latest figure at $141.2 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 21.19% year-over-year to $141.2 million in Q2 2026; TTM through Jun 2026 was $141.2 million, a 21.19% decrease from a year earlier, with the FY2025 full-year figure at $124.5 million, down 35.06% from the prior year.
• Cash & Equivalents was $141.2 million for Q2 2026 at Cellebrite DI, up from $133.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $281.4 million in Q3 2025, with the low at $84.6 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $132.8 million, with a median of $125.1 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 39.96% in 2023, then surged 118.68% in 2024.
• Over 5 years, Cash & Equivalents stood at $146.0 million in 2022, then slumped by 39.96% to $87.6 million in 2023, then jumped by 118.68% to $191.7 million in 2024, then plunged by 35.06% to $124.5 million in 2025, then climbed by 13.49% to $141.2 million in 2026.
• The last three Cash & Equivalents figures came in at $141.2 million (Q2 2026), $133.7 million (Q1 2026), and $124.5 million (Q4 2025), per Business Quant data.